Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer’s Disease

Medicine & Life Sciences

• Polypharmacy 100%
• Cholinesterase Inhibitors 94%
• Rivastigmine 80%
• Galantamine 79%
• Donepezil 73%
• Comorbidity 63%
• Alzheimer Disease 63%
• Dementia 45%
• Lewy Body Disease 34%
• Vascular Dementia 33%
• Medication Adherence 30%
• Drug-Related Side Effects and Adverse Reactions 25%
• Cognitive Dysfunction 22%
• Elderly 18%
• Costs and Cost Analysis 16%
• Pharmaceutical Preparations 11%
• Therapeutics 4%

Social Sciences

• comorbidity 99%
• beneficial effects 92%
• dementia 82%
• medication 23%
• drug 18%
• cognitive impairment 16%
• cause 8%
• costs 7%
• event 7%
• interaction 6%
• evidence 5%
• literature 5%